YOLFTbeta
Corline Biomedical AB

Corline Biomedical AB

CLBIO · ST · Healthcare / Biotechnology

14.20SEK+0.10 (+0.71%)

Price History

Full chart

Market Stats

Previous Close14.10
Open14.10
Day Range13.15 – 14.90
52-Week Range13.15 – 22.30
Volume15.20K
Market Cap397.22M
P/E (TTM)0.00
Forward P/E2.41
EPS-0.48
Dividend Yield0.00%
Beta0.29
50-Day Avg16.48
200-Day Avg16.77

About

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Henrik Nittmar Ph.D.
  • Employees14
  • HeadquartersLefflersgatan 5, Uppsala, Sweden, 754 50, Sweden
  • Websitehttps://www.corline.se

Leadership

  • Dr. Henrik Nittmar Ph.D.Chief Executive Officer · b. 1966
  • Ms. Asa HolmChief Operating Officer

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.00M1.79M1.68M1.04M947.00K638.00K1.56M1.06M3.70M7.06M23.55M25.03M9.78M7.65M
Growth (%)--70.20%-5.84%-38.39%-8.69%-32.63%+144.98%-31.93%+247.37%+91.07%+233.47%+6.28%-60.95%-21.73%
Cost of Revenue135.05K-2.24M-1.71M-2.16M-6.50M-33.00K-4.97M-6.08M-6.62M-2.04M824.00K-3.35M-3.67M21.86M
Gross Profit5.86M4.03M3.39M3.20M7.45M671.00K6.53M7.15M10.32M9.10M22.73M28.38M13.44M-14.21M
Gross Margin97.75%225.27%201.43%308.62%786.69%105.17%417.72%671.71%279.22%128.89%96.50%113.38%137.50%-185.70%
Operating Expense6.70M6.44M5.89M8.88M12.67M8.48M13.32M16.69M17.61M16.01M20.40M30.17M36.61M0
Operating Income-833.32K-2.42M-2.50M-5.68M-5.22M-7.81M-6.79M-9.54M-7.29M-6.91M2.33M-1.79M-23.17M-14.21M
Operating Margin-13.89%-135.21%-148.63%-547.33%-551.21%-1223.82%-434.55%-896.62%-197.16%-97.83%9.89%-7.14%-236.99%-185.70%
EBITDA-807.49K-2.38M-2.45M-5.65M-5.22M-7.81M-6.79M-9.53M-7.27M-6.88M2.38M-1.69M-23.07M-14.12M
EBITDA Margin-13.46%-133.32%-145.26%-544.60%-551.00%-1223.67%-434.48%-895.77%-196.73%-97.39%10.13%-6.74%-235.98%-184.60%
Net Income-911.47K-2.49M-2.51M-5.85M-5.25M-7.81M-6.79M-9.54M-7.29M-6.92M2.33M-1.81M-23.19M-14.71M
Net Income Margin-15.19%-139.17%-149.25%-563.62%-554.17%-1224.14%-434.61%-896.62%-197.16%-97.93%9.89%-7.23%-237.28%-192.31%
Interest Expense-77.44K33.35K169.77K28.00K1.00K1.00K012.00K13.00K026.00K32.00K1.00K
Interest Expense % of Total Revenue-4.33%1.98%16.37%2.96%0.16%0.06%0.00%0.32%0.18%0.00%0.10%0.33%0.01%

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.46M13.76M16.77M24.99M41.27M51.43M62.91M63.75M58.28M101.66M101.78M100.11M94.76M98.58M
Total Liabilities11.09M5.76M11.29M3.74M2.53M5.50M7.95M4.43M6.25M9.43M7.19M6.79M7.85M4.82M
Total Equity584.73K8.00M5.48M21.25M38.75M45.93M54.96M59.32M52.03M92.23M94.59M93.32M86.91M93.76M
Cash2.34M1.18M1.64M4.87M11.86M16.86M27.64M22.86M8.99M41.63M26.21M17.01M17.67M20.56M
Total Debt-3.55M9.31M-----------
Net Debt-2.34M2.37M7.67M-4.87M-11.86M-16.86M-27.64M-22.86M-8.99M-41.63M-26.21M-17.01M-17.67M-20.56M

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--2.76M-2.32M-4.23M-7.21M-4.98M-4.10M-13.84M-5.07M-4.83M-6.45M886.00K-8.64M-17.69M
Investing Cash Flow--3.08M-2.72M-4.84M-8.54M-5.02M-937.00K-4.84M-8.80M-9.56M-9.00M-10.62M-7.50M-982.00K
Financing Cash Flow-4.68M5.50M12.30M22.74M14.99M15.83M13.90M47.13M47.13M26.00K537.00K16.79M21.56M
Capital Expenditure03.08M2.72M4.84M8.54M5.02M937.00K4.84M8.80M9.62M9.00M10.62M7.50M47.00K
Free Cash Flow--5.84M-5.04M-9.08M-15.75M-10.00M-5.04M-18.68M-13.87M-14.45M-15.45M-9.73M-16.14M-17.74M
FCF to OCF-211.80%217.21%214.49%218.37%200.84%122.83%135.00%273.71%298.90%239.48%-1098.76%186.78%100.27%

Earnings

Report DateJun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020May 10, 2021Aug 25, 2021Nov 25, 2021Feb 23, 2022May 13, 2022Aug 25, 2022Nov 25, 2022Feb 24, 2023Apr 28, 2023Aug 25, 2023Nov 10, 2023Feb 14, 2024Apr 30, 2024Aug 23, 2024Nov 7, 2024Feb 17, 2025May 8, 2025Aug 26, 2025Sep 30, 2025Feb 16, 2026May 6, 2026Jun 30, 2026
EPS Estimate---------------------------------------------
EPS Actual-0.16-0.11-0.22-0.19-0.05-0.10-0.12-0.24-0.16-0.07-0.11-0.12-0.12-0.09-0.10-0.18-0.15-0.11-0.12-0.15-0.15-0.13-0.00-0.08-0.10-0.10-0.06-0.040.040.090.020.05-0.110.01-0.03-0.08-0.20-0.14-0.62-0.13-0.13-0.14-0.20-0.10-0.05
Surprise---------------------------------------------
Timing--------------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap397.22M
Enterprise Value342.02M
Trailing P/E0.00
Forward P/E2.41
Price / Sales32.07
Price / Book3.79
EPS-0.48
Book Value3.79
Revenue (TTM)12.39M
Gross Profit (TTM)10.98M
EBITDA-12.31M
Profit Margin-99.47%
Operating Margin-31.49%
Return on Equity-13.72%
Return on Assets-7.74%
Shares Outstanding26.13M
Shares Float11.30M
Beta0.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 4, 20211051:1022
  • Mar 14, 2016668:661